A principal investigator (PI) does not disengage because enrollment is slow. A PI disengages when the trial goes quiet — when weeks pass with no update on screening, no visibility into referrals, and no recognition for the chart review and pre-screening work already done. Sites that keep a PI engaged through a slow stretch do three things: they keep the PI in the loop with a short, regular update, they tie compensation to defined activities rather than enrollment alone, and they ask directly what is slowing referrals instead of assuming it is motivation.
Record storage is not a closeout task. It is a multi-year obligation that starts the day a trial closes, and the sites that price it at signing — as its own annual budget line, split between physical and electronic records, with the retention period agreed in writing — are the ones that do not discover the cost years later, when the sponsor relationship has moved on and there is no amendment left to negotiate.
November 16, 2026·Amavita Editorial (AI-assisted) AI-assisted
A US clinical trial site needs the protocol and schedule of activities to price a study budget. What the site does with it, and what sponsors and CROs can send up front.
A mobile research unit — a van or trailer equipped for study visits outside the clinic — solves a real access problem, but it does not move a whole protocol off-site. The visits that move safely are routine, low-acuity assessments: vital signs, blood draws, and electrocardiograms (ECGs) performed by trained staff with the right equipment. The visits that stay in clinic are infusions, complex procedures, and anything that could need immediate escalation. Everything in between is a sponsor decision, and it has to be made — with protocol language and budget agreed — before the van is treated as a recruitment tool.
A clinical trial management system (CTMS) is good at recording that an invoice was issued. It is poor at making sure the invoice gets paid. Sites that rely on their CTMS for accounts receivable (A/R) end up with a complete list of invoices and an incomplete picture of what is owed, because the system tracks billing events, not the follow-up each unpaid invoice still needs. The fix is a small routine that lives outside the CTMS: one aging tracker, pulled weekly, reviewed at 30, 60, and 90 days, with one named owner and one named next action for every overdue line.
Long-term cardiovascular (CV) trials do not lose participants at the annual visit. They lose them in the long, quiet stretch between visits, when nobody is funded to make the contact attempts, keep vital status current, and keep the principal investigator (PI) reviewing follow-up data. Most budgets pay for the visit itself and leave that between-visit retention work unfunded, so sites absorb it until they cannot. A budget amendment fixes the problem only if it prices the right thing: an annual amount tied to the active follow-up population, with the oversight work named for what the protocol actually requires.
RECIST disagreements are usually handoff failures, not software failures. One named trained reader per study, a second read for borderline lesions, trained backups, and one SOP for capture, measurement, and filing create an audit trail that stands on its own.
November 6, 2026·Amavita Editorial (AI-assisted) AI-assisted
How continuous remote ECG after same-day discharge supports early cardiovascular feasibility safety windows under 21 CFR Part 11, without replacing investigator oversight.
November 6, 2026·Amavita Editorial (AI-assisted) AI-assisted
When early-phase cardiovascular trials compete with hospital operations, enrollment slows. Dedicated telemetry beds, cath-lab access and coordinators change the clocks.
If QA cites a manufacturer requirement, ask for the manual page. When the manual is silent, set a defensible interval in your SOP, log every event — inconsistency is what creates findings.
Regulatory upkeep, pharmacy monitoring, system subscriptions, trainings: fixed per-trial costs sites fold into overhead and never recover. Cost the baseline and present it as an annual study-management fee.
Importing a messy spreadsheet imports the mess. Clean and dedupe before import, agree status definitions in writing, test-import a batch, and set a hard cutover date — no parallel running.
Entering clinical data in both an internal tracker and the sponsor system creates discrepancies and PHI exposure. Work in the system of record; keep the internal list minimal — identifier, status, next action.
Vendor demos sell the demo. Build a test study from your own SOPs in the sandbox and make every candidate CTMS run it end to end — then price integrations, the AI roadmap, and switching costs.
Job boards miss experienced coordinators. Source through referrals, write the real job into the posting, and screen with a de-identified schedule-of-assessments exercise instead of resume years.
Extensions with two to four visits a year cannot carry fixed costs on per-visit pay. Unbundle regulatory upkeep, pharmacy oversight, and retention into an annual maintenance fee at the amendment.
The greenfield kit for cardio-metabolic work: 12-lead ECG with QTcF reporting, Holter and ambulatory blood pressure, refrigerated centrifuge, monitored cold storage — and logs running from day one.
Sponsors ask how a site audits itself. A written QA plan, scheduled internal audits, CAPA discipline, and role-based training records make a standalone site read as inspection-ready.
Price is the last criterion. Judge inventory software on investigational product accountability at inspection, links to storage temperature excursions, and whether coordinators will use it daily.
Free sponsor-supplied routine-care medications change your coverage analysis and raise inducement questions. Work through both, avoid the billing traps, and negotiate the opt-out before you sign.
When a protocol assumes equipment the sponsor does not provide, the site absorbs the capital cost. Spot the gap at feasibility, decide buy vs. lease on total cost, and negotiate it into the budget.
No public benchmark exists for screen-fail, unscheduled-visit, or post-lock query fees. Build each fee from the work itself — itemized labor and resources — and define the event in the budget exhibit.
Rural enrollment dies on transportation. Who funds participant transport, what sponsors expect in the plan, and the practical models — vouchers, mileage, visit clustering — that keep rural participants enrolled.
Start-up and close-out work, amendments, re-consenting, extra monitoring support, retention: the study-level items sites perform but never invoice. How to spot, document, and bill each one.
New sites face a catch-22: sponsors screen on history the site cannot have yet. Registry studies, a one-page capability snapshot, and fast honest feasibility answers break it.
Do not buy artificial intelligence as a platform. Pilot one named workflow — pre-screening chart review, follow-up, documentation — measure time saved and errors, keep eligibility decisions human.
Recruitment work goes unfunded when the plan reads as narrative. Structure it with headings that translate line by line into the budget: chart review, outreach, retention, transport, contingency.
Bringing in an outside specialist for one procedure? Price it as a flat fee per completed procedure, all-inclusive, paid by the site under a budget exhibit — research-only, never billed to insurance.
For sponsors and CROs: what makes a US site's clinical trial agreement move faster. Reuse an agreement already negotiated, price standard budget lines in a rate card, settle the legal entity and signer at the start, and run IRB work alongside the contract where the sponsor and IRB allow it.
October 29, 2026·Amavita Editorial (AI-assisted) AI-assisted
Vendor demos follow the vendor's script. How to sandbox-test a CTMS against your own SOPs, source workflow, integrations and finance reports before you sign.
October 26, 2026·Amavita Editorial (AI-assisted) AI-assisted
What 21 CFR 56.108, 56.110, 812.35 and 312.30 require for protocol amendments, where the time goes, and how a Miami cardiovascular site keeps enrollment moving through version changes.
October 26, 2026·Amavita Editorial (AI-assisted) AI-assisted
How to design early feasibility protocols for catheter-based devices with same-day observation, and what sponsors check when a US cardiology site brings in an outside implanting surgeon or procedure operator.
October 26, 2026·Amavita Editorial (AI-assisted) AI-assisted
Why a dedicated cardiovascular ASC research setting in Miami can start daytime device protocols faster than a tertiary hospital, and when it is the wrong choice.
October 13, 2026·Amavita Editorial (AI-assisted) AI-assisted
Indication map, diagnostics, and same-day Phase 1 work (2 operating rooms and 5 recovery beds in a licensed Kendall cardiovascular ASC) at Amavita Research — without overnight or non-CV claims.
October 13, 2026·Amavita Editorial (AI-assisted) AI-assisted
Amavita Research recruits from an active Miami cardiovascular practice panel instead of waiting on passive referrals. What that changes for screening — and what it does not promise.
Used equipment can build a good site — or quietly disqualify it. Before buying a used ECG or other device for trial work: verify the calibration and service paper trail, confirm the digital export formats central laboratories require, budget IQ/OQ qualification, and run the total cost of ownership.
October 5, 2026·Amavita Editorial (AI-assisted) AI-assisted
Amavita Research is a cardiovascular site. How we plan to add immunology and pursue imaging-enabled oncology and neurology scopes as prime site, and what is not true yet.
October 5, 2026·Amavita Editorial (AI-assisted) AI-assisted
Amavita Research runs cardiovascular Phase 1 work inside an affiliated Kendall, Miami ASC licensed for 2 operating rooms and 5 recovery beds. Same-day outpatient scope.
August 25, 2026·Amavita Editorial (AI-assisted) AI-assisted
Heart failure affects over 6 million adults in the US. Learn about the types, stages, modern treatment options, and how clinical trials are advancing care.
August 22, 2026·Amavita Editorial (AI-assisted) AI-assisted
TAVR has evolved beyond the high-risk population. Here is what referring cardiologists need to know about patient selection, procedural advances, and when to refer in 2026.
How FDA's Diversity Action Plan Final Guidance affects cardiovascular trial site selection: enrollment targets, site demographic profile, sponsor obligations, and how sites like Amavita Research support diverse enrollment in Miami.
When to run a cardiovascular trial across US and Latin America under a single coordinated design: speed-to-FIH, regulatory pathways, patient diversity, cost arbitrage, and operational integration. Amavita Research + bioaccess®.
Comprehensive sponsor decision criteria for evaluating cardiovascular clinical trial sites in 2026: PI continuity, patient flow, contracting speed, cost structure, quality framework, and indication fit.
Plain-language guide for patients considering enrollment in a cardiovascular clinical trial: screening, informed consent, randomization, time commitment, compensation, your rights, and what to expect at every stage.
Plain-language guide to reading a clinical trial informed consent form: what each section means, which sections matter most, common red flags, and questions to ask the trial team before signing.
Plain-language guide for patients with structural heart disease (TAVR candidates, mitral valve, congenital adult patients) considering clinical trial participation. Eligibility, what trials are testing, what to expect.
Plain-language guide for patients who have had a heart attack or unstable angina considering clinical trial participation: what trials are testing, eligibility, what to expect, and current ACS trials at Amavita Research.
Plain-language guide for heart failure patients with iron deficiency considering clinical trial participation: why iron deficiency matters in HF, what IV iron trials are testing, eligibility, what to expect.
Plain-language guide for patients with peripheral artery disease considering clinical trial participation: what trials are testing in 2026, eligibility, what to expect, and current PAD trials at Amavita Research.
Plain-language guide for patients with high blood pressure considering clinical trial participation: what trials are testing in 2026, eligibility, what to expect, and current hypertension trials at Amavita Research in North Miami Beach, FL.
Plain-language guide for patients with heart failure considering clinical trial participation: what trials are testing in 2026, eligibility, what to expect, and current heart failure trials at Amavita Research in North Miami Beach, FL.
Amavita Research is GCSA-certified (recertified May 13, 2026, valid to Feb 28, 2027), meeting the Global Quality Standard for Clinical Research Sites established by IAOCR.
On May 13, 2026, Amavita Research performed a coronary stent procedure at the affiliated Kendall ASC (Advanced Cardiovascular of Miami) — a dedicated cardiovascular ambulatory surgery center (ASC) in Miami-Dade. The procedure was led by Dr. Pedro Martinez-Clark.
April 29, 2026·Amavita Editorial (AI-assisted) AI-assisted
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart's main pumping chamber squeezes normally but is too stiff to relax and fill with blood properly betwee
April 29, 2026·Amavita Editorial (AI-assisted) AI-assisted
Heart failure with reduced ejection fraction (HFrEF) is a type of heart failure where the heart's main pumping chamber does not squeeze out enough blood with each beat.[1][2][3]
April 29, 2026·Amavita Editorial (AI-assisted) AI-assisted
A pacemaker is a small, battery-powered device implanted under the skin in the chest that helps your heart beat at a normal, steady rhythm by sending mild electrical impulses when needed.
From the first phone call through the final follow-up visit, here is a step-by-step look at what participating in a cardiovascular clinical trial actually involves.
Drug clinical trials are organized into phases. Each one answers different safety and effectiveness questions. Here is what each phase is for, in plain language.
First-in-human (FIH) trials are the first time a new therapy is studied in people. Here is how protocols, oversight, and site experience combine to keep participants safe.
Atherectomy is an endovascular technique that removes or modifies arterial plaque, often used in calcified peripheral artery disease. Here is how it works.
PAD affects millions of adults in the U.S. Learn the warning signs, how it is diagnosed, and the modern range of treatment options — including ongoing clinical research.
TAVR is a minimally invasive procedure that replaces a diseased aortic valve through a catheter — without open-heart surgery. Here is how it works and who it helps.
Eligibility for a cardiovascular clinical trial depends on the study's protocol — but the basic principles are the same across trials. Here is how qualification works.
A clear, plain-language explanation of cardiovascular clinical trials — what they study, how they protect participants, and the role they play in advancing heart and vascular care.